Rarebase
Transcripta Bio is a pioneering drug discovery company leveraging AI and high-throughput transcriptomic data to map how drugs affect gene expression across 20,000 genes. Their platform integrates advanced lab screening of thousands of molecules with AI-driven predictions to design novel drug candidates that modulate cellular functions. By combining structural and systems biology, they accelerate therapeutic discovery, focusing on diseases with clear genetic causality, including rare diseases. Their proprietary Drug-Gene Atlas and Conductor AI enable rapid virtual screening of billions of compounds, facilitating biomarker development and clinical translation. The company operates a high-fidelity human cell line screening process and synthesizes molecules in-house, positioning itself as a leader in scalable, transcriptome-driven drug discovery with strong investor backing and partnerships.
Rarebase
Transcripta Bio is a pioneering drug discovery company leveraging AI and high-throughput transcriptomic data to map how drugs affect gene expression across 20,000 genes. Their platform integrates advanced lab screening of thousands of molecules with AI-driven predictions to design novel drug candidates that modulate cellular functions. By combining structural and systems biology, they accelerate therapeutic discovery, focusing on diseases with clear genetic causality, including rare diseases. Their proprietary Drug-Gene Atlas and Conductor AI enable rapid virtual screening of billions of compounds, facilitating biomarker development and clinical translation. The company operates a high-fidelity human cell line screening process and synthesizes molecules in-house, positioning itself as a leader in scalable, transcriptome-driven drug discovery with strong investor backing and partnerships.